Suzanne Lentzsch, MD, PhD

Medical Oncology
Cancer Care, Hematology
More specialties
Accepting New Patients
Virtual Visits/Telehealth
Profile Headshot



Dr. Lentzsch is a Professor of Clinical Medicine and the Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York. She is at New York Presbyterian Hospital/ Columbia University Medical Center. After receiving her degrees from the Humboldt University/ Charité Berlin, Germany, she completed her residency and fellowship at Humboldt University. She did a research fellowship, studying the mechanism of action of thalidomide and its derivatives in multiple myeloma, in the Jerome Lipper Multiple Myeloma Center under the mentorship of Dr Kenneth Anderson at the Dana-Farber Cancer Institute, Boston, MA, USA.

Dr. Lentzsch was recruited in August 2004 to the University of Pittsburgh and University of Pittsburgh Cancer Institute (UPCI), PA, USA, and served as Clinical Director of the Multiple Myeloma Program at UPCI before accepting the position as Director of the Multiple Myeloma and Amyloidosis Program at Columbia University Medical Center. She cares primarily for patients with plasma cell dyscrasia including MGUS, Multiple Myeloma, Amyloidosis, POEMS and Waldenstrom's Macroglobulinemia.

Dr. Lentzsch is an internationally recognized expert in the field of Multiple Myeloma and Amyloidosis. She serves as a SWOG Myeloma Committee Member, SWOG Study Coordinator and International Myeloma Foundation "Black Swan Research Initiative" committee member. She is a member of the standing advisory board for the evaluation of Secondary Primary Malignancies associated with IMiDs.

Areas of Expertise / Conditions Treated

  • Amyloidosis
  • Bone Marrow Transplant
  • MGUS (Monoclonal Gammopathy of Unknown Significance)
  • Multiple Myeloma
  • Peripheral Stem Cell Transplant
  • POEMS Syndrome
  • Waldenstrom's Disease

Academic Appointments

  • Professor of Medicine

Administrative Titles

  • Director, Multiple Myeloma and Amyloidosis Program

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center
  • NewYork-Presbyterian Westchester


  • German


  • Female

Schedule an Appointment

Virtual Visits/Telehealth

Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.

Schedule Virtual Visit

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In


161 Fort Washington Avenue
New York, NY 10032

Insurance Accepted

Affinity Health Plan

  • Essential Plan
  • Medicaid Managed Care


  • Medicare Managed Care
  • Special Needs

Amida Care

  • Special Needs


  • EPO
  • Great West (National)
  • HMO
  • Medicare Managed Care
  • POS
  • PPO


  • Medicare Managed Care
  • PPO


  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care


  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare (National)

  • MagnaCare


  • Railroad
  • Traditional Medicare


  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Quality Health Management

  • Quality Health Management


  • Special Needs


  • Compass (Exchange)
  • Empire Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • Oxford Freedom
  • Oxford HMO
  • Oxford Liberty
  • POS
  • PPO


  • Medicaid Managed Care
  • Medicare Managed Care

World Trade Center Health Plan

  • World Trade Center Health Plan

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • Humboldt University, Faculty of Medicine (Germany)
  • Internship: Humboldt University, Faculty of Medicine (Germany)
  • Residency: Humboldt University, Faculty of Medicine (Germany)
  • Fellowship: Dana Farber Cancer Institute-Harvard Medical School
  • Fellowship: Humboldt University, Faculty of Medicine (Germany)

Committees, Societies, Councils

  • German Society of Cancer
  • American Society of Hematology
  • American Association for Cancer Reseach
  • American Society of Clinical Oncology
  • International Myeloma Working Group
  • International Myeloma Society
  • Herbert Irving Comprehensive Cancer Center in Lymphoid Development and Malignancy
  • ECOG Auditor
  • SWOG Study Coordinator
  • SWOG Myeloma Committee Member
  • Herbert Irving Comprehensive Cancer Center Protocol Review and Monitoring Committee

Honors & Awards

  • 2014: Leukemia Lymphoma Society, Woman of the year Candidate
  • 2014 - 2015: MMRF Laugh for Life Honorary Chair
  • 2012: ASH Advocacy Leadership Institute
  • 2012 - 2013:  “Leukemia Diploma For a selection of worthy articlesin 2012/2013” by Editor in Chief, Leukemia
  • 2012:Japanese Society of Hematology Appreciation Award
  • 2009: UPCI Junior Scholar Award in Clinical Cancer Research
  • 2005: Research Day Awardee, Junior Faculty Category, University of Pittsburgh School of Medicine, Department of Medicine Third Annual Research Day
America's Top Doctor
NY Top Doctor


Dr Lentzsch' translational laboratory research work provided critical insights to understanding of the mechanism of action of thalidomide and IMiDs in multiple myeloma and bone disease. With the goal to bring findings from bench to beside, her current RO1 funded laboratory research investigates the role of metallo-proteinases in multiple myeloma bone disease in order to develop new strategies to target myeloma bone disease.

Dr Lentzsch is leading many phase 1, 2 and 3 clinical trials, including investigator-initiated studies for amyloidosis, newly diagnosed and relapsed/refractory multiple myeloma and for maintenance following transplant for multiple myeloma. She currently focuses on the evaluation of the monoclonal antibody 11-1F4 targeting amyloid directly and thereby inducing the break –up of amyloid. Further Dr. Lentzsch served as national principal investigator in Germany evaluating the role of lenalidomide in the treatment of relapsed Multiple Myeloma and is leading an international multicenter trial to evaluate the role of Xofigo in relapsed refractory multiple myeloma. As Co-Chair of the Pathways Committee, she played a major role in the development of the Multiple Myeloma Pathways at University Pittsburgh Medical Center.

Her research is funded by various grants and awards from e.g. the NIH, Pennsylvania Department of Health, the German Cancer Foundation, the Leukemia and Lymphoma Society , the Multiple Myeloma Research Foundation and the International Myeloma Foundation. Dr Lentzsch has published over 70 original articles, editorials, chapters, many as the lead or senior author, in such prestigious journals as Journal of Clinical Investigations, Blood, Cancer Research, and Leukemia.